董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hing C. Wong | 男 | Chief Executive Officer and Director | 72 | 43.87万美元 | 52.19 | 2026-01-30 |
| Lisa M. Giles | 女 | Independent Director | 67 | 未披露 | 未持股 | 2026-01-30 |
| Rick S. Greene | 男 | Independent Director | 61 | 5.00万美元 | 0.43 | 2026-01-30 |
| Lisa M. Giles | 女 | Independent Director | 67 | 4.00万美元 | 0.35 | 2026-01-30 |
| Scott T. Garrett | 男 | Chairman of the Board and Independent Director | 75 | 6.00万美元 | 2.77 | 2026-01-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hing C. Wong | 男 | Chief Executive Officer and Director | 72 | 43.87万美元 | 52.19 | 2026-01-30 |
| Rebecca Byam | 女 | Chief Financial Officer | 70 | 30.93万美元 | 4.84 | 2026-01-30 |
| Lee Flowers | 男 | Senior Vice President of Business Development | 80 | 未披露 | 未持股 | 2026-01-30 |
| Peter Rhode | 男 | Chief Scientific Officer and Vice President of Clinical Operations | 68 | 26.39万美元 | 0.32 | 2026-01-30 |
董事简历
中英对照 | 中文 | 英文- Hing C. Wong
-
Hing C.Wong自2018年4月起担任我们的首席执行官。在创立我们公司之前，2002年至2017年8月，黄博士创立并担任Altor Bioscience Corporation的首席执行官，当时该公司被NantCell，Inc.收购，随后成为ImmunityBio，Inc.。收购Altor后，他担任NantCell的首席执行官至2018年3月。在此之前，Wong博士从1996年到2002年创立并担任Sunol Molecular Corporation的首席执行官，从1992年到1996年担任Baxter医疗保健Inc.的生物技能中心主任，从1983年到1992年担任Cetus Corporation的微生物遗传学主任。Wong博士在麻省大学安默斯特分校获得了微生物学和免疫学博士学位，并在华盛顿大学完成了博士后培训。
Hing C. Wong has served as Founder and Chief Executive Officer since April 2018. Prior to founding Company, Dr. Wong founded and served as the Chief Executive Officer of Altor BioScience Corporation, from 2002 to Augt 2017, when it was acquired by NantCell, Inc. (which subsequently became ImmunityBio, Inc.). After the acquisition of Altor, he served as the Chief Executive Officer of NantCell until March 2018. Prior to that, Dr. Wong founded and served as Chief Executive Officer of Sunol Molecular Corporation from 1996 to 2002; the Director, Biology Skills Center of Baxter Healthcare Inc. from 1992 to 1996; and the Director of Microbial Genetics of Cet Corporation from 1983 to 1992. Dr. Wong received his Ph.D. degree in Microbiology and Immunology at the University of Massachetts, Amherst and completed his postdoctoral training at the University of Washington. - Hing C.Wong自2018年4月起担任我们的首席执行官。在创立我们公司之前，2002年至2017年8月，黄博士创立并担任Altor Bioscience Corporation的首席执行官，当时该公司被NantCell，Inc.收购，随后成为ImmunityBio，Inc.。收购Altor后，他担任NantCell的首席执行官至2018年3月。在此之前，Wong博士从1996年到2002年创立并担任Sunol Molecular Corporation的首席执行官，从1992年到1996年担任Baxter医疗保健Inc.的生物技能中心主任，从1983年到1992年担任Cetus Corporation的微生物遗传学主任。Wong博士在麻省大学安默斯特分校获得了微生物学和免疫学博士学位，并在华盛顿大学完成了博士后培训。
- Hing C. Wong has served as Founder and Chief Executive Officer since April 2018. Prior to founding Company, Dr. Wong founded and served as the Chief Executive Officer of Altor BioScience Corporation, from 2002 to Augt 2017, when it was acquired by NantCell, Inc. (which subsequently became ImmunityBio, Inc.). After the acquisition of Altor, he served as the Chief Executive Officer of NantCell until March 2018. Prior to that, Dr. Wong founded and served as Chief Executive Officer of Sunol Molecular Corporation from 1996 to 2002; the Director, Biology Skills Center of Baxter Healthcare Inc. from 1992 to 1996; and the Director of Microbial Genetics of Cet Corporation from 1983 to 1992. Dr. Wong received his Ph.D. degree in Microbiology and Immunology at the University of Massachetts, Amherst and completed his postdoctoral training at the University of Washington.
- Lisa M. Giles
-
Lisa M. Giles自2021年10月起担任董事会董事。自2000年以来，Giles女士创立并担任生命科学工业和学术医疗中心咨询公司Giles & Associates Consultancy，Inc.（GAC）的董事总经理和首席执行官。除了HCW Biologics，Giles女士目前还担任Milestone制药董事会成员和Northstern Memorial Health System Foundation董事会成员。She Previoly于2015年至2021年担任GenMark Diagnostics的董事会成员；2012年至2014年担任Durata Therapeutics，以及2005年至2006年担任Intranasal Therapeutics，Inc.的董事会成员。2013年至2019年，她还是广汽集团的姊妹公司Optivara，Inc.的创始人兼首席执行官。在创立GAC之前，Giles女士是孟山都旗下分部G.D. Searle Pharmaceutical的战略发展副总裁，并在雅培担任过多个领导职务。Giles女士在Juniata学院获得经济学学士学位，并在斯坦福大学和芝加哥大学完成了高管管理课程。
Lisa M. Giles has served on board of directors since October 2021. Ms. Giles founded and has served as the Managing Director and Chief Executive Officer of Giles & Associates Consultancy, Inc. (GAC), a consulting firm in the life sciences indtry and academic medical centers, since 2000. In addition to HCW Biologics, Ms. Giles currently serves as a member of the board of directors for Milestone Pharmaceuticals and the Northstern Memorial Health System Foundation Board. She previoly served as a member of the board of directors for GenMark Diagnostics from 2015 to 2021; Durata Therapeutics, Inc. from 2012 to 2014, and Intranasal Therapeutics, Inc. from 2005 to 2006. She also was the Founder and Chief Executive Officer of Optivara, Inc. a sister company to GAC, from 2013 to 2019. Prior to founding GAC, Ms. Giles was the Vice President of strategy development at G.D. Searle Pharmaceutical, a division of Monsanto, and held vario leadership roles with Abbott Laboratories. Ms. Giles received her B.S. in economics from Juniata College and completed executive management programs at Stanford University and the University of Chicago. - Lisa M. Giles自2021年10月起担任董事会董事。自2000年以来，Giles女士创立并担任生命科学工业和学术医疗中心咨询公司Giles & Associates Consultancy，Inc.（GAC）的董事总经理和首席执行官。除了HCW Biologics，Giles女士目前还担任Milestone制药董事会成员和Northstern Memorial Health System Foundation董事会成员。She Previoly于2015年至2021年担任GenMark Diagnostics的董事会成员；2012年至2014年担任Durata Therapeutics，以及2005年至2006年担任Intranasal Therapeutics，Inc.的董事会成员。2013年至2019年，她还是广汽集团的姊妹公司Optivara，Inc.的创始人兼首席执行官。在创立GAC之前，Giles女士是孟山都旗下分部G.D. Searle Pharmaceutical的战略发展副总裁，并在雅培担任过多个领导职务。Giles女士在Juniata学院获得经济学学士学位，并在斯坦福大学和芝加哥大学完成了高管管理课程。
- Lisa M. Giles has served on board of directors since October 2021. Ms. Giles founded and has served as the Managing Director and Chief Executive Officer of Giles & Associates Consultancy, Inc. (GAC), a consulting firm in the life sciences indtry and academic medical centers, since 2000. In addition to HCW Biologics, Ms. Giles currently serves as a member of the board of directors for Milestone Pharmaceuticals and the Northstern Memorial Health System Foundation Board. She previoly served as a member of the board of directors for GenMark Diagnostics from 2015 to 2021; Durata Therapeutics, Inc. from 2012 to 2014, and Intranasal Therapeutics, Inc. from 2005 to 2006. She also was the Founder and Chief Executive Officer of Optivara, Inc. a sister company to GAC, from 2013 to 2019. Prior to founding GAC, Ms. Giles was the Vice President of strategy development at G.D. Searle Pharmaceutical, a division of Monsanto, and held vario leadership roles with Abbott Laboratories. Ms. Giles received her B.S. in economics from Juniata College and completed executive management programs at Stanford University and the University of Chicago.
- Rick S. Greene
-
Rick S. Greene于2011年被任命为首席财务官。自2011年4月起出任财政会计的临时副总裁。拥有超过25年的财务管理和报告经验。从2007年至2011年，曾在Crowe Horwath的田纳西州医疗实践工作，担任市场领导者，建立并领导服务于团队私募股权投资公司，技术、医药和其他医疗保健公司的财务顾问队伍。从2005年到2007年担任LBMC医疗集团的金融服务总监。此前，自2002至2005年担任Surgical Alliance Corporation（一家专科医院公司）的财务总监，Phycor公司（一家公开上市的医生管理公司）的财务运营总监。在全国会计师事务所安永会计师事务所任职14年，担任各类要职。持有 Carson-Newman学院的理学士学位。
Rick S. Greene has served on board of directors since May 2021. Mr. Greene is currently the Chief Financial Officer of Specialized Dental Partners. Prior to joining Specialized Dental Partners in May 2023, Mr. Greene served as the Chief Financial Officer of Epiphany Dermatology from March 2018 to May 2023. Mr. Greene served as the Chief Financial Officer of Altor BioScience Corporation from 2015 to 2018, Vice President and Chief Financial Officer of Cumberland Pharmaceuticals from 2011 to 2015, Executive at Cro Horwath LLP from 2007 to 2011, Director at LBMC from 2005 to 2007, Chief Financial Officer at Surgical Alliance Corporation from 2002 to 2005, Senior Manager at Ernst & Young LLP from 1998 to 2002 and 1987 to 1997, and Director Financial Operations at Phycor Inc. from 1997 to 1998. Mr. Greene received his B.S. degree in accounting from Carson Newman University and is currently registered as a Certified Public Accountant (inactive) in the state of Tennessee. - Rick S. Greene于2011年被任命为首席财务官。自2011年4月起出任财政会计的临时副总裁。拥有超过25年的财务管理和报告经验。从2007年至2011年，曾在Crowe Horwath的田纳西州医疗实践工作，担任市场领导者，建立并领导服务于团队私募股权投资公司，技术、医药和其他医疗保健公司的财务顾问队伍。从2005年到2007年担任LBMC医疗集团的金融服务总监。此前，自2002至2005年担任Surgical Alliance Corporation（一家专科医院公司）的财务总监，Phycor公司（一家公开上市的医生管理公司）的财务运营总监。在全国会计师事务所安永会计师事务所任职14年，担任各类要职。持有 Carson-Newman学院的理学士学位。
- Rick S. Greene has served on board of directors since May 2021. Mr. Greene is currently the Chief Financial Officer of Specialized Dental Partners. Prior to joining Specialized Dental Partners in May 2023, Mr. Greene served as the Chief Financial Officer of Epiphany Dermatology from March 2018 to May 2023. Mr. Greene served as the Chief Financial Officer of Altor BioScience Corporation from 2015 to 2018, Vice President and Chief Financial Officer of Cumberland Pharmaceuticals from 2011 to 2015, Executive at Cro Horwath LLP from 2007 to 2011, Director at LBMC from 2005 to 2007, Chief Financial Officer at Surgical Alliance Corporation from 2002 to 2005, Senior Manager at Ernst & Young LLP from 1998 to 2002 and 1987 to 1997, and Director Financial Operations at Phycor Inc. from 1997 to 1998. Mr. Greene received his B.S. degree in accounting from Carson Newman University and is currently registered as a Certified Public Accountant (inactive) in the state of Tennessee.
- Lisa M. Giles
-
这是LisaM.GilesGiles女士自2015年2月起担任公司董事会成员。自2000年以来，Giles女士一直担任Giles&Associates Consultancy，Inc.的首席执行官兼总裁，这是一家为生命科学和梦百合行业客户服务的战略咨询公司，她于2000年成立了该公司。Giles女士还于2012年创立了Optivara，Inc.，并目前担任其首席执行官，该公司是一家软件SaaS公司，也服务于生命科学行业。2000年之前，Giles女士担任G.D.Searle&Company的战略与发展Vice President，负责全球制药战略规划、投资组合决策分析、投资组合优化和交易分析。Giles女士此前曾于2012年8月至2014年11月被Actavis plc收购期间担任DurataTherapeutics，Inc.董事会成员。Giles女士是西北纪念医院基金会（Northwestern Memorial Hospital Foundation）董事会和芝加哥艺术研究所（Art Institute of Chicago）名誉退休辅助委员会的受托人。Giles女士持有Juniata College的B.S.，并完成了Stanford University和University of Chicago的执行管理课程。2015年，Giles女士被PharmaVoice评为“生命科学最具影响力的100强人物”之一。
Lisa M. Giles. Ms. Giles has served on the Company's Board since February 2015. Since 2000 Ms. Giles has served as CEO and President of Giles & Associates Consultancy, Inc., a strategy consulting firm serving life science and healthcare industry clients, which she formed in 2000. In 2012 Ms. Giles also founded and currently serves as the CEO of Optivara, Inc., a software Saas company also serving the life sciences industry. Prior to 2000 Ms. Giles served as Vice President of Strategy and Development for G.D. Searle & Company, where she oversaw global pharmaceutical strategic planning, portfolio decision analysis, portfolio optimization and transaction analysis. Ms. Giles previously served as a member of the board of directors of Durata Therapeutics, Inc., from August 2012 until its acquisition by Actavis plc in November 2014. Ms. Giles is a trustee on the board of Northwestern Memorial Hospital Foundation and the emeritus Auxilary Board of the Art Institute of Chicago. Ms. Giles holds a B.S. from Juniata College and completed the executive management program at Stanford University and The University of Chicago. In 2015 Ms. Giles was recognized by PharmaVoice as one of the "Top 100 Most Influential People in Life Sciences". - 这是LisaM.GilesGiles女士自2015年2月起担任公司董事会成员。自2000年以来，Giles女士一直担任Giles&Associates Consultancy，Inc.的首席执行官兼总裁，这是一家为生命科学和梦百合行业客户服务的战略咨询公司，她于2000年成立了该公司。Giles女士还于2012年创立了Optivara，Inc.，并目前担任其首席执行官，该公司是一家软件SaaS公司，也服务于生命科学行业。2000年之前，Giles女士担任G.D.Searle&Company的战略与发展Vice President，负责全球制药战略规划、投资组合决策分析、投资组合优化和交易分析。Giles女士此前曾于2012年8月至2014年11月被Actavis plc收购期间担任DurataTherapeutics，Inc.董事会成员。Giles女士是西北纪念医院基金会（Northwestern Memorial Hospital Foundation）董事会和芝加哥艺术研究所（Art Institute of Chicago）名誉退休辅助委员会的受托人。Giles女士持有Juniata College的B.S.，并完成了Stanford University和University of Chicago的执行管理课程。2015年，Giles女士被PharmaVoice评为“生命科学最具影响力的100强人物”之一。
- Lisa M. Giles. Ms. Giles has served on the Company's Board since February 2015. Since 2000 Ms. Giles has served as CEO and President of Giles & Associates Consultancy, Inc., a strategy consulting firm serving life science and healthcare industry clients, which she formed in 2000. In 2012 Ms. Giles also founded and currently serves as the CEO of Optivara, Inc., a software Saas company also serving the life sciences industry. Prior to 2000 Ms. Giles served as Vice President of Strategy and Development for G.D. Searle & Company, where she oversaw global pharmaceutical strategic planning, portfolio decision analysis, portfolio optimization and transaction analysis. Ms. Giles previously served as a member of the board of directors of Durata Therapeutics, Inc., from August 2012 until its acquisition by Actavis plc in November 2014. Ms. Giles is a trustee on the board of Northwestern Memorial Hospital Foundation and the emeritus Auxilary Board of the Art Institute of Chicago. Ms. Giles holds a B.S. from Juniata College and completed the executive management program at Stanford University and The University of Chicago. In 2015 Ms. Giles was recognized by PharmaVoice as one of the "Top 100 Most Influential People in Life Sciences".
- Scott T. Garrett
-
Scott T. Garrett，2013年5月加入Hologic, Inc.董事会。Garrett先生目前是Water Street Healthcare Partners的高级运营合伙人，Water Street Healthcare Partners是一家专注于医疗保健行业的战略投资者。在全球医疗保健行业从业约35年后，他于2011年加入Water Street。在加入Water Street之前，Garrett先生曾于2008年至2011年担任领先的生物医药公司Beckman Coulter的董事长、总裁兼首席执行官。Garrett先生于2002年加入Beckman Coulter，担任临床诊断部门总裁，并于2003年晋升为总裁兼首席运营官。2005年1月，他成为首席执行官，并于2008年增加了主席一职。在此之前，Garrett先生曾于1999年至2001年担任Kendro实验室产品公司的副主席兼临时首席执行官。从1994年到1998年，他担任Dade Behring的董事长、总裁和首席执行官，这是一家领先的诊断公司。他的职业生涯始于美国医院供应公司，并在American Hospital Supply Corporation被Baxter International收购后继续任职，最终担任Baxter 全球实验室业务百特诊断的首席执行官。Garrett还在Water Street拥有所有权的公司的董事会任职。Garrett在Valparaiso University获得机械工程学学士学位，并在Lake Forest管理研究生院获得工商管理硕士学位。
Scott T. Garrett has served on board of directors since May 2021 and as Chairman of the board since June 2021. Mr. Garrett is currently a Senior Operating Partner at Water Street Healthcare Partners ("Water Street"). Prior to joining Water Street in 2011, Mr. Garrett served as Chairman, President and Chief Executive Officer of Beckman Coulter, Inc. from 2008 to 2011. Mr. Garrett joined Beckman Coulter, Inc. in 2002 as President, Clinical Diagnostics Division and was promoted to President and Chief Operating Officer in 2003. In January 2005, he became Chief Executive Officer and in 2008, added the position of Chairman. Prior to that, Mr. Garrett served as Vice Chairman and Interim Chief Executive Officer of Kendro Laboratory Products from 1999 to2001; Chairman, President and Chief Executive Officer of Dade Behring, a leading diagnostics company, from 1994 to 1998; and Managing Partner of Garrett Capital Advisors, First Chicago Equity Capital from 1998 to 2002. Mr. Garrett began his career at American Hospital Supply Corporation and continued there after the company was acquired by Baxter International, ultimately serving as Chief Executive of Baxter International's global laboratory biness, Baxter Diagnostics from 1992 to 1994. Mr. Garrett also served on the board of Hologic, Inc. from 2013 until March 2025. He currently serves on the board of MeMed Diagnostics; and in his role at Water Street, he chairs the boards of vario portfolio companies, including Alcor Scientific, Pathnostics and Avantik. He also serves on the board of the Advanced Medical Technology Association Diagnostics and its Executive Committee. Mr. Garrett received his B.S. degree in mechanical engineering from Valparaiso University and an M.B.A. from the Lake Forest Graduate School of Management. He also completed the Executive Management program at Stanford Graduate School of Biness. - Scott T. Garrett，2013年5月加入Hologic, Inc.董事会。Garrett先生目前是Water Street Healthcare Partners的高级运营合伙人，Water Street Healthcare Partners是一家专注于医疗保健行业的战略投资者。在全球医疗保健行业从业约35年后，他于2011年加入Water Street。在加入Water Street之前，Garrett先生曾于2008年至2011年担任领先的生物医药公司Beckman Coulter的董事长、总裁兼首席执行官。Garrett先生于2002年加入Beckman Coulter，担任临床诊断部门总裁，并于2003年晋升为总裁兼首席运营官。2005年1月，他成为首席执行官，并于2008年增加了主席一职。在此之前，Garrett先生曾于1999年至2001年担任Kendro实验室产品公司的副主席兼临时首席执行官。从1994年到1998年，他担任Dade Behring的董事长、总裁和首席执行官，这是一家领先的诊断公司。他的职业生涯始于美国医院供应公司，并在American Hospital Supply Corporation被Baxter International收购后继续任职，最终担任Baxter 全球实验室业务百特诊断的首席执行官。Garrett还在Water Street拥有所有权的公司的董事会任职。Garrett在Valparaiso University获得机械工程学学士学位，并在Lake Forest管理研究生院获得工商管理硕士学位。
- Scott T. Garrett has served on board of directors since May 2021 and as Chairman of the board since June 2021. Mr. Garrett is currently a Senior Operating Partner at Water Street Healthcare Partners ("Water Street"). Prior to joining Water Street in 2011, Mr. Garrett served as Chairman, President and Chief Executive Officer of Beckman Coulter, Inc. from 2008 to 2011. Mr. Garrett joined Beckman Coulter, Inc. in 2002 as President, Clinical Diagnostics Division and was promoted to President and Chief Operating Officer in 2003. In January 2005, he became Chief Executive Officer and in 2008, added the position of Chairman. Prior to that, Mr. Garrett served as Vice Chairman and Interim Chief Executive Officer of Kendro Laboratory Products from 1999 to2001; Chairman, President and Chief Executive Officer of Dade Behring, a leading diagnostics company, from 1994 to 1998; and Managing Partner of Garrett Capital Advisors, First Chicago Equity Capital from 1998 to 2002. Mr. Garrett began his career at American Hospital Supply Corporation and continued there after the company was acquired by Baxter International, ultimately serving as Chief Executive of Baxter International's global laboratory biness, Baxter Diagnostics from 1992 to 1994. Mr. Garrett also served on the board of Hologic, Inc. from 2013 until March 2025. He currently serves on the board of MeMed Diagnostics; and in his role at Water Street, he chairs the boards of vario portfolio companies, including Alcor Scientific, Pathnostics and Avantik. He also serves on the board of the Advanced Medical Technology Association Diagnostics and its Executive Committee. Mr. Garrett received his B.S. degree in mechanical engineering from Valparaiso University and an M.B.A. from the Lake Forest Graduate School of Management. He also completed the Executive Management program at Stanford Graduate School of Biness.
高管简历
中英对照 | 中文 | 英文- Hing C. Wong
Hing C.Wong自2018年4月起担任我们的首席执行官。在创立我们公司之前，2002年至2017年8月，黄博士创立并担任Altor Bioscience Corporation的首席执行官，当时该公司被NantCell，Inc.收购，随后成为ImmunityBio，Inc.。收购Altor后，他担任NantCell的首席执行官至2018年3月。在此之前，Wong博士从1996年到2002年创立并担任Sunol Molecular Corporation的首席执行官，从1992年到1996年担任Baxter医疗保健Inc.的生物技能中心主任，从1983年到1992年担任Cetus Corporation的微生物遗传学主任。Wong博士在麻省大学安默斯特分校获得了微生物学和免疫学博士学位，并在华盛顿大学完成了博士后培训。
Hing C. Wong has served as Founder and Chief Executive Officer since April 2018. Prior to founding Company, Dr. Wong founded and served as the Chief Executive Officer of Altor BioScience Corporation, from 2002 to Augt 2017, when it was acquired by NantCell, Inc. (which subsequently became ImmunityBio, Inc.). After the acquisition of Altor, he served as the Chief Executive Officer of NantCell until March 2018. Prior to that, Dr. Wong founded and served as Chief Executive Officer of Sunol Molecular Corporation from 1996 to 2002; the Director, Biology Skills Center of Baxter Healthcare Inc. from 1992 to 1996; and the Director of Microbial Genetics of Cet Corporation from 1983 to 1992. Dr. Wong received his Ph.D. degree in Microbiology and Immunology at the University of Massachetts, Amherst and completed his postdoctoral training at the University of Washington.- Hing C.Wong自2018年4月起担任我们的首席执行官。在创立我们公司之前，2002年至2017年8月，黄博士创立并担任Altor Bioscience Corporation的首席执行官，当时该公司被NantCell，Inc.收购，随后成为ImmunityBio，Inc.。收购Altor后，他担任NantCell的首席执行官至2018年3月。在此之前，Wong博士从1996年到2002年创立并担任Sunol Molecular Corporation的首席执行官，从1992年到1996年担任Baxter医疗保健Inc.的生物技能中心主任，从1983年到1992年担任Cetus Corporation的微生物遗传学主任。Wong博士在麻省大学安默斯特分校获得了微生物学和免疫学博士学位，并在华盛顿大学完成了博士后培训。
- Hing C. Wong has served as Founder and Chief Executive Officer since April 2018. Prior to founding Company, Dr. Wong founded and served as the Chief Executive Officer of Altor BioScience Corporation, from 2002 to Augt 2017, when it was acquired by NantCell, Inc. (which subsequently became ImmunityBio, Inc.). After the acquisition of Altor, he served as the Chief Executive Officer of NantCell until March 2018. Prior to that, Dr. Wong founded and served as Chief Executive Officer of Sunol Molecular Corporation from 1996 to 2002; the Director, Biology Skills Center of Baxter Healthcare Inc. from 1992 to 1996; and the Director of Microbial Genetics of Cet Corporation from 1983 to 1992. Dr. Wong received his Ph.D. degree in Microbiology and Immunology at the University of Massachetts, Amherst and completed his postdoctoral training at the University of Washington.
- Rebecca Byam
Rebecca Byam自2019年10月起担任我们的首席财务官。在加入我们公司之前，Byam女士从2003年到2019年担任PricewaterhouseCoopers LLP的董事，从1998年到2002年担任Mamamedia Inc.的首席财务官，从1995年到1998年担任Momentum Partners的首席财务官，并担任Apax Partners LLP的投资专业人员，从1985年到1995年，她专注于生物技术投资和其他具有强大知识产权的领域。此外，Byam女士在投资咨询委员会任职，协助美国小企业管理局的小企业投资公司计划的发展。Byam女士在凯尼恩学院（Kenyon College）获得文理学士学位，在纽约大学斯特恩商学院（New York University Stern School of Business）获得工商管理硕士学位，主修金融。她目前在佛罗里达州和纽约州注册为注册会计师。
Rebecca Byam has served as Chief Financial Officer since October 2019. Prior to joining company, Ms. Byam served as a Director of PricewaterhoeCoopers LLP from 2003 to 2019; the Chief Financial Officer of MaMaMedia Inc. from 1998 to 2002; the Chief Financial Officer of Momentum Partners from 1995 to 1998; and as an Investment Professional at Apax Partners LLP, where she specialized in biotechnology investments among other areas with strong intellectual property, from 1985 to 1995. Additionally, Ms. Byam served on the Investment Advisory Council, assisting the development of the Small Biness Investment Company program of the U.S. Small Biness Administration. Ms. Byam received a B.A. degree in liberal arts from Kenyon College and an M.B.A from the New York University Stern School of Biness with a major in finance. She is currently registered as a Certified Public Accountant in the states of Florida and New York.- Rebecca Byam自2019年10月起担任我们的首席财务官。在加入我们公司之前，Byam女士从2003年到2019年担任PricewaterhouseCoopers LLP的董事，从1998年到2002年担任Mamamedia Inc.的首席财务官，从1995年到1998年担任Momentum Partners的首席财务官，并担任Apax Partners LLP的投资专业人员，从1985年到1995年，她专注于生物技术投资和其他具有强大知识产权的领域。此外，Byam女士在投资咨询委员会任职，协助美国小企业管理局的小企业投资公司计划的发展。Byam女士在凯尼恩学院（Kenyon College）获得文理学士学位，在纽约大学斯特恩商学院（New York University Stern School of Business）获得工商管理硕士学位，主修金融。她目前在佛罗里达州和纽约州注册为注册会计师。
- Rebecca Byam has served as Chief Financial Officer since October 2019. Prior to joining company, Ms. Byam served as a Director of PricewaterhoeCoopers LLP from 2003 to 2019; the Chief Financial Officer of MaMaMedia Inc. from 1998 to 2002; the Chief Financial Officer of Momentum Partners from 1995 to 1998; and as an Investment Professional at Apax Partners LLP, where she specialized in biotechnology investments among other areas with strong intellectual property, from 1985 to 1995. Additionally, Ms. Byam served on the Investment Advisory Council, assisting the development of the Small Biness Investment Company program of the U.S. Small Biness Administration. Ms. Byam received a B.A. degree in liberal arts from Kenyon College and an M.B.A from the New York University Stern School of Biness with a major in finance. She is currently registered as a Certified Public Accountant in the states of Florida and New York.
- Lee Flowers
Lee Flowers自2019年9月起担任业务发展高级副总裁。在加入我们公司之前，Flowers先生从1994年到1996年担任Dade International（百特国际有限公司的分拆公司）的执行副总裁；Baxter Diagnostics，百特国际有限公司’；S最大子公司的风险开发副总裁，从1993年到1994年，担任Baxter Diagnostics的部门总裁（从1991年到1993年）。在美国医院供应公司（American Hospital Supply Corporation）和百特国际有限公司’；的前身公司合并后，Flowers先生于1990年担任Dade部门的全球营销副总裁，并于1986年至1989年担任Paramax系统部门的副总裁兼销售与市场营销。弗劳尔斯先生在肯塔基大学获得生物学学士学位。
Lee Flowers has served as Senior Vice President of Biness Development since September 2019. Mr. Flowers is also the Co Founder of HRS Consulting Inc. Prior to joining company, in 2009, Mr. Flowers cofounded HRS Consulting, Inc., a Service Disabled Veteran Owned Small Biness specializing in management consulting, which acquired the healthcare biness of Convergent HRS, LLC and Convergent Knowledge Solutions, LLC, binesses he also cofounded in 2007 and 2003 respectively. He served as the CEO of Sunol Molecular, Inc from 2001 to 2002, CEO of Continuum Electro optics, Inc from 1997 to 2001; Executive Vice President of Dade International, a spin off of Baxter International Inc., from 1994 to 1996; the Vice President of Venture Development at Baxter Diagnostics, Baxter International Inc.'s largest subsidiary, from 1993 to 1994; and Division President at Baxter Diagnostics from 1992 to 1993. Upon the merger beten American Hospital Supply Corporation and Baxter International Inc.'s predecessor, Mr. Flowers served as Vice President of Global Marketing for the Dade Division from 1990 to 1991 and Vice President, Sales and Marketing for the Paramax Systems Division from 1986 to1989 at the merged entity. Mr. Flowers received his bachelor's degree in zoology from the University of Kentucky.- Lee Flowers自2019年9月起担任业务发展高级副总裁。在加入我们公司之前，Flowers先生从1994年到1996年担任Dade International（百特国际有限公司的分拆公司）的执行副总裁；Baxter Diagnostics，百特国际有限公司’；S最大子公司的风险开发副总裁，从1993年到1994年，担任Baxter Diagnostics的部门总裁（从1991年到1993年）。在美国医院供应公司（American Hospital Supply Corporation）和百特国际有限公司’；的前身公司合并后，Flowers先生于1990年担任Dade部门的全球营销副总裁，并于1986年至1989年担任Paramax系统部门的副总裁兼销售与市场营销。弗劳尔斯先生在肯塔基大学获得生物学学士学位。
- Lee Flowers has served as Senior Vice President of Biness Development since September 2019. Mr. Flowers is also the Co Founder of HRS Consulting Inc. Prior to joining company, in 2009, Mr. Flowers cofounded HRS Consulting, Inc., a Service Disabled Veteran Owned Small Biness specializing in management consulting, which acquired the healthcare biness of Convergent HRS, LLC and Convergent Knowledge Solutions, LLC, binesses he also cofounded in 2007 and 2003 respectively. He served as the CEO of Sunol Molecular, Inc from 2001 to 2002, CEO of Continuum Electro optics, Inc from 1997 to 2001; Executive Vice President of Dade International, a spin off of Baxter International Inc., from 1994 to 1996; the Vice President of Venture Development at Baxter Diagnostics, Baxter International Inc.'s largest subsidiary, from 1993 to 1994; and Division President at Baxter Diagnostics from 1992 to 1993. Upon the merger beten American Hospital Supply Corporation and Baxter International Inc.'s predecessor, Mr. Flowers served as Vice President of Global Marketing for the Dade Division from 1990 to 1991 and Vice President, Sales and Marketing for the Paramax Systems Division from 1986 to1989 at the merged entity. Mr. Flowers received his bachelor's degree in zoology from the University of Kentucky.
- Peter Rhode
Peter Rhode自2019年5月起担任我们的首席科学官兼临床运营副总裁。在加入我们公司之前，Rhode博士在Altor Bioscience Corporation于2017年4月被NantCell，Inc.收购后担任研究与开发的高级副总裁，该公司随后成为ImmunityBio，Inc.直到2019年。在此之前，从2002年Altor Bioscience Corporation成立到被Nantcell，Inc.收购，Rhode博士担任其副总裁兼研究与开发。Rhode博士是1996年成立Sunol Molecular Corporation的科学家团队中的一员，从1996年到2002年担任Sunol Molecular的研究总监。从1991年到1996年，Rhode博士还担任百特国际有限公司的高级科学家。罗德博士在加州大学戴维斯分校获得学士学位，在威斯康星大学麦迪逊分校获得生物化学/生物物理学博士学位。此外，罗德博士还是加州理工学院的博士后。
Peter Rhode has served as Chief Scientific Officer and Vice President of Clinical Operations since May 2019. Prior to joining company, Dr. Rhode served as the Senior Vice President of Research and Development at Altor BioScience Corporation following its April 2017 acquisition by NantCell, Inc. (which subsequently became ImmunityBio, Inc.) until 2019. Prior to that, Dr. Rhode served as Vice President, Research and Development at Altor BioScience Corporation from its inception in 2002 until its acquisition by NantCell, Inc. Dr. Rhode was among the team of scientists that formed Sunol Molecular Corporation in 1996 and served as Research Director at Sunol Molecular from 1996 to 2002. Dr. Rhode also served as Senior Scientist at Baxter International Inc. from 1991 to 1996. Dr. Rhode received his B.S. degree at the University of California, Davis and his Ph.D. in Biochemistry/Biophysics at the University of Wisconsin, Madison. Additionally, Dr. Rhode was a postdoctoral fellow at the California Institute of Technology.- Peter Rhode自2019年5月起担任我们的首席科学官兼临床运营副总裁。在加入我们公司之前，Rhode博士在Altor Bioscience Corporation于2017年4月被NantCell，Inc.收购后担任研究与开发的高级副总裁，该公司随后成为ImmunityBio，Inc.直到2019年。在此之前，从2002年Altor Bioscience Corporation成立到被Nantcell，Inc.收购，Rhode博士担任其副总裁兼研究与开发。Rhode博士是1996年成立Sunol Molecular Corporation的科学家团队中的一员，从1996年到2002年担任Sunol Molecular的研究总监。从1991年到1996年，Rhode博士还担任百特国际有限公司的高级科学家。罗德博士在加州大学戴维斯分校获得学士学位，在威斯康星大学麦迪逊分校获得生物化学/生物物理学博士学位。此外，罗德博士还是加州理工学院的博士后。
- Peter Rhode has served as Chief Scientific Officer and Vice President of Clinical Operations since May 2019. Prior to joining company, Dr. Rhode served as the Senior Vice President of Research and Development at Altor BioScience Corporation following its April 2017 acquisition by NantCell, Inc. (which subsequently became ImmunityBio, Inc.) until 2019. Prior to that, Dr. Rhode served as Vice President, Research and Development at Altor BioScience Corporation from its inception in 2002 until its acquisition by NantCell, Inc. Dr. Rhode was among the team of scientists that formed Sunol Molecular Corporation in 1996 and served as Research Director at Sunol Molecular from 1996 to 2002. Dr. Rhode also served as Senior Scientist at Baxter International Inc. from 1991 to 1996. Dr. Rhode received his B.S. degree at the University of California, Davis and his Ph.D. in Biochemistry/Biophysics at the University of Wisconsin, Madison. Additionally, Dr. Rhode was a postdoctoral fellow at the California Institute of Technology.